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Exocrine pancreatic insufficiency (EPI) is rare in children, with most if not all cases 
occurring as part of syndromic conditions such as cystic fibrosis and Shwachman-Diamond 
syndrome. Here we report two cases, both presenting with severe EPI around five months of 
age. Characterized by diffuse pancreatic lipomatosis, they otherwise exhibited no remarkable 
deficiencies in other organs. Novel non-identical homozygous variants (a deletion removing 
the entire SPINK1 gene and an insertion of a full-length inverted Alu element into the 3'-
untranslated region of the SPINK1 gene) resulting in the complete functional loss of 
the SPINK1 gene (encoding pancreatic secretory trypsin inhibitor) were identified in each 
patient. Having correlated our findings with current knowledge of SPINK1’s role in exocrine 
pancreas pathophysiology, we propose that complete and partial functional losses of 
the SPINK1 gene are associated with quite distinct phenotypes, the former causing a new 
pediatric disease entity of severe infantile isolated EPI. 
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Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the 
exocrine pancreatic enzymes, resulting in an inability to digest food properly. The hallmark 
symptoms of severe EPI are weight loss and loose fatty stools termed 
steatorrhea (Struyvenberg et al., 2017). Chronic pancreatitis is the leading cause of 
EPI in adults (Pezzilli et al., 2013). Severe EPI due to chronic pancreatitis in 
children is rare for two interrelated reasons. First, chronic pancreatitis is a 
persistent inflammatory process of the pancreas, generally requiring a significant 
period of time for EPI to develop (Layer et al., 1994). Second, severe EPI appears 
only once pancreatic enzyme output falls below 5-10% of normal (DiMagno et al., 
1973). Characteristic radiographic features of chronic pancreatitis include 
pancreatic ductal dilation and parenchymal calcification (Majumder and Chari, 
2016). 
The primary causes of severe EPI in children are cystic fibrosis and Shwachman-
Diamond syndrome (Buscail and Carrière, 2010), which are caused by mutations in 
the CFTR (MIM# 602421) and SBDS (MIM# 607444) genes (Boocock et al., 2003; 
Kerem et al., 1989), respectively. Besides EPI, affected patients typically display 
other abnormalities e.g. lung inflammation/infection in cystic fibrosis, and 
hematological abnormalities with single- or multi-lineage cytopenias and bone 
abnormalities in Shwachman-Diamond syndrome. The typical pathological finding 
in the pancreas of patients with Shwachman-Diamond syndrome is fatty 
infiltration, termed pancreatic lipomatosis (Robberecht et al., 
1985). Pancreatic lipomatosis is also a frequent finding in older patients with cystic 
fibrosis (Soyer et al., 1999). Severe EPI in children can also arise from some other 
rarer syndromic conditions such as Pearson syndrome and Johanson-Blizzard 
syndrome. Nonetheless, in all the aforementioned syndromic conditions, a clinical 
diagnosis can usually be easily made, due to their corresponding hallmark 
phenotypic manifestations. Herein we describe the first report of two cases of 
severe infantile isolated EPI and the identification of their underlying genetic 
causes. 
Case 1 was born at term, with a normal weight (3310 g), height (47 cm) and head 
circumference (33 cm), to first cousin consanguineous parents of Turkish origin (Fig. 1A). 
The patient's family medical history was unremarkable. At five months of age, she 
presented with failure to thrive (weight, 4.940 kg, −2.5 SD; height, 54 cm, −3 SD; 
head circumference, 38 cm, −3 SD) and erythemato-squamous skin lesions. She 
was exclusively breast-fed and did not have bowel problems. Clinical examination 
revealed facial dysmorphism (large cheeks, nasal alae hypoplasia, crooked and 
brittle hair), but no other anomaly – no hepatosplenomegaly in particular. Clinical 
laboratory tests showed undernutrition, malabsorption, and mixed cytolytic and 
cholestatic liver damage without liver cell insufficiency (Supp. Table S1). The 
patient's metabolic (ammonemia, blood and urine carnitine level, blood 
acylcarnitine analysis, blood amino acid and urine organic acid chromatographies) 
and immune (lymphocyte subpopulation counts, serum immunoglobulin 
concentrations, vaccine-induced antibody titers) function was found to be normal. 
In addition, no immunoallergic reactions were discovered: radioallergosorbent tests 
for cow's milk protein, anti-trans-glutaminase antibodies and anti-enterocyte 
antibodies were all negative. Skin biopsies revealed psoriasis-like dermatitis 
(parakeratosis without necrosis). Hair analysis showed the absence of hair breaks 
or nodosities, allowing us to rule out tricho-hepato-enteric syndrome, and pointing 
instead towards nutritional deficiency. The patient's gastroscopy and colonoscopy 
were both normal; however, an abdominal ultrasound scan revealed a 
hyperechogenic pancreas of normal size. Magnetic resonance imaging of the 
patient's pancreas performed secondarily at five years of age revealed major fatty 
infiltration throughout (Fig. 1B; Supp. Fig. S1). The patient's fecal elastase 
concentration (5 μg/g, N > 200) and steatorrhea after fat intake (7.8 g/d) confirmed 
the diagnosis of EPI. Pancreatic enzyme replacement therapy was initiated, and the 
patient was given parenteral nutrition for two weeks with a gradual reintroduction 
of enteral feeding using a hypoallergenic infant formula (Peptijunior, Picot) 
containing extensively hydrolyzed proteins. Subsequently, her liver function and 
growth rate returned to normal and her skin lesions disappeared. At six years of 
age, her weight, height and head circumference were 18.2 kg, 105.5 cm and 51 cm, 
respectively and she was symptom-free with normal intellectual development. 
Case 2 was born at term, with a normal weight (2700 g) and height (50 cm), to first 
cousin consanguineous parents of Algerian origin (Fig. 2A). She had fatty stools 
since five months of age. When she was first examined by us at 32 months of age, 
her weight was 14.3 kg (+1 SD) and her height was 93 cm (+1 SD); a 24-hour fecal 
fat test showed 45.5 g/d fat (normal, around 1), chymotrypsin activity of 0.4 Q/g 
(normal, > 6) and an elastase concentration of < 15 mg/g (normal, > 200) in the 
stool; serum concentrations of vitamins D, A and E were significantly decreased; 
all other laboratory and clinical examinations were normal. Magnetic resonance 
imaging performed at three years of age showed a normal sized pancreas with 
diffuse lipomatosis but with neither dilatation of the canal of Wirsung nor presence 
of intraparenchymal nodules; her liver, kidneys, spleen and gallbladder showed 
normal morphologies and were all of normal size. She received enzyme 
replacement therapy and, when was examined at five years of age, was 21 kg (+1.5 
SD) in weight and 116 cm (+2 SD) in height. Her father and paternal grandmother 
had complained of recurrent abdominal pain. 
Cases 1 and 2 were initially analyzed for mutations in the CFTR and SBDS genes, both 
yielding negative findings. They were then analyzed for mutations in three trypsin-dependent 
pathway genes causing chronic pancreatitis (Hegyi and Sahin-Tóth, 2017), 
namely PRSS1 (MIM# 276000), SPINK1 (MIM# 167790) and CTRC (MIM# 
601405) (Le Maréchal et al., 2006; Masson et al., 2008; Rosendahl et al., 2008; 
Whitcomb et al., 1996; Witt et al., 2000). No disease-causing mutations were found 
in the PRSS1 and CTRC genes whilst two novel SPINK1 gene mutations were 
found in the homozygous state. Methods pertaining to mutational analyses of 
the SPINK1 gene as well as the functional analyses described below are provided 
in Supp. Methods as well as in Supp. Table S2 and Fig. S2. Written consent was 
obtained from each patient’s parents and the Ethical Committees of the involved 
services approved genetic analyses. 
In case 1, high-resolution DNA melting (HRM) analysis of the patient indicated no 
amplification of any of the four exons of the SPINK1 gene, suggesting a homozygous 
deletion of the entire gene. We confirmed this by means of our previously 
established quantitative fluorescent multiplex PCR (QFM-PCR) assay (Masson et 
al., 2007) (Fig. 1C). Walking QFM-PCR (Masson et al., 2007) was then employed 
to narrow down the deletion breakpoints, a strategy which led to the capture of the 
aberrant chromosomal junction by long-range PCR (Fig. 1D). Sequencing of the 
purified 3.5kb patient-specific product established the deletion as being 37,194bp 
in length, stretching from c.-28211 to c.*2066 (the first nucleotide of the 
translational initiation codon ATG is termed c.1 and the first nucleotide 3' of the 
translation stop codon is termed c.*1, in accordance with (den Dunnen et al., 
2016)) or from chr5:147822595 to chr5:147859788 (hg38) (Fig. 1E). This deletion 
involved only the SPINK1gene. 
In case 2, HRM analysis of the patient’s genomic DNA showed that the first 
three amplicons of the four-exon SPINK1 gene had similar melting curve patterns 
to those of normal controls but the fourth and last amplicon of the gene was absent 
(Fig. 2B). One possible reason for this latter finding would be the presence of an 
insertion within the target sequence in both alleles. We therefore increased the 
extension time of the PCR cycle from 30 to 45 seconds, and this yielded a single 
PCR product in the patient, ~400bp longer than its wild-type counterpart; this 
product was also present in both parents (Fig. 2C). Sequencing of this longer PCR 
product revealed the insertion of an inverted full-length Alu sequence (precisely 
359 bp in length) between nucleotides c.*14 and c.*15 in the 3'-untranslated region 
(3'-UTR) of the SPINK1 gene (for further details of the mutation, see Supp. Fig. 
S3). The inserted sequence belongs to Alu Yb9, the youngest subfamily 
of Alu elements. Based upon an extensive literature search, we believe that this 
variant represents the first report of an Alu insertion into the 3’-UTR of a human 
gene causing genetic disease (Chen et al., 2006; Chen et al., 2005). 
We analyzed the effect of the Alu insertion on SPINK1 gene expression in the 
context of a full-length gene assay. Briefly, we cloned both the full length wild-
type SPINK1 genomic sequence (7217bp; extending from the translational 
initiation codon to c.*300) and its 7576 bp mutant counterpart into the 
pcDNA3.1/V5-His-TOPO vector. Reverse transcription-PCR (PT-PCR) of 
mRNAs from HEK293T transfected with the mutant construct did not yield any 
specific products; the 300bp RT-PCR product from HEK293T cells transfected 
with the wild-type construct (Fig. 2D) was confirmed by sequencing to be the 
wild-type SPINK1 transcript. Moreover, we established long-term culture of 
Epstein-Barr virus-immortalized peripheral blood lymphocytes from the patient. 
RT-PCR analysis of mRNAs from the resulting cultured lymphocytes did not 
reveal any PCR products; by contrast, expression of the SPINK1 gene was detected 
in the Epstein-Barr virus-immortalized lymphocytes from a healthy control (Fig. 
2E). 
To the best of our knowledge, no similar cases of severe infantile isolated EPI have ever 
been reported in the literature. Our two patients shared remarkably similar phenotypic 
manifestations, namely the occurrence of severe EPI from the age of five months, early 
appearance of diffusepancreatic lipomatosis (apparently at an age younger than five and three 
years, respectively), absence of significant abnormalities in any other organs, and normal 
growth and development upon enzyme replacement therapy. We adopted a reductionist 
approach to identify the genetic defect underlying this previously undescribed phenotypic 
profile. Thus, we first searched for mutations in CFTR and SBDS, the two primary causes of 
severe EPI in children. When this search for causative mutations proved negative, we turned 
to the PRSS1, SPINK1 and CTRC genes, mutations in which either cause or predispose to 
chronic pancreatitis. Two novel and non-identical homozygous mutations were identified in 
the SPINK1genes of the two patients. 
SPINK1 encodes pancreatic secretory trypsin inhibitor, which has long been 
considered to be the first line of defense against prematurely activated trypsin 
within the pancreas (reviewed in (Chen and Férec, 2009)). A diverse range of loss 
of function mutations in the SPINK1 gene have already been reported to 
cause/predispose to chronic pancreatitis 
(see http://www.pancreasgenetics.org/index.php). The most 
deleterious SPINK1genotype so far reported is consequent to homozygosity for 
c.194+2T>C. Based upon functional analysis performed using a full-length gene 
splicing assay (Zou et al., 2016) and RT-PCR analysis performed using gastric 
tissue from a c.194+2T>C homozygote (Kume et al., 2006), we surmise that ~10% 
of normal SPINK1 function would be present in the pancreas of a c.194+2T>C 
homozygote. Notably, c.194+2T>C homozygotes were reported to show extreme 
phenotypic variability, albeit with stones or calcification in the pancreas being 
common findings; the earliest onset of pancreatitis was reported to be at five years 
of age although none of the studied patients including a 75-year-old male, had 
developed severe EPI (Ota et al., 2010). The next most 
deleterious SPINK1 genotypes, which include those heterozygous SPINK1variants 
that render the affected alleles completely nonfunctional (such as large deletions 
and frameshifting variants) have also been reported to cause chronic 
pancreatitis (Le Maréchal et al., 2004; Masson et al., 2006). By contrast, less 
deleterious SPINK1genotypes exemplified by the haplotype harboring 
the SPINK1 c.101A>G (p.Asn34Ser) variant are generally considered to represent 
predisposing rather than a causative factors for chronic pancreatitis (Boulling et al., 
2017). In short, SPINK1 genotypes that do not result in a complete functional loss 
of the SPINK1 gene tend either to predispose or to cause chronic pancreatitis. 
In case 1, the functional consequence of the mutation identified, which removed the 
entire SPINK1 gene but did not affect any other genes, is straightforward. In case 2, the 
mutation identified was an insertion of a full-length, inverted Alu element into the 3'-UTR of 
the SPINK1 gene. We performed functional analysis using a full-length gene assay; the 
resulting complete loss of SPINK1 expression was corroborated by RT-PCR analysis of 
mRNA from patient-derived cultured lymphocytes. The pathogenic relevance of two 
homozygous null mutations, involving a gene that plays an important role in pancreatic 
pathophysiology, and identified in two patients with severe infantile isolated EPI, is thus self-
evident. In this regard, it is pertinent to relate our current findings to those obtained 
with Spink3-deficient (Spink3−/−) mice (Ohmuraya et al., 2005) [murine Spink3 and 
human SPINK1 are orthologous]. In Spink3−/− mice, autophagic degradation of 
acinar cells occurred from day 16.5 after coitus; rapid onset of cell death occurred 
in the pancreas within a few days of birth, leading to death by the age of 14.5 days. 
Importantly, the massive amount of acinar cell death in Spink3−/− mice was 
associated neither with substantial infiltration of inflammatory cells nor with 
apoptosis (Ohmuraya et al., 2005). Whether or not the pancreatic damage 
in Spink3-deficient mice was trypsin-dependent (Ohmuraya et al., 2006) remains to 
be further investigated. Although physiological and pathological differences exist 
between human and mouse models, it is evident that a complete functional loss of 
the SPINK1 gene and a partial functional loss of the SPINK1 gene are associated 
with quite distinct clinical phenotypes. 
There is an additional point to make. The parents of cases 1 and 2 were not subjected to 
genetic analysis but they should be obligate carriers of the respective variants. We do not 
possess laboratory test and imaging data with respect to the structure and function of the 
pancreas for any of the parents. As mentioned earlier, the father and paternal grandmother of 
case 2 had complained of recurrent abdominal pain, suggesting the existence of chronic 
pancreatitis; by contrast, the parents of case 1 were reportedly healthy. In this context, it is 
pertinent to mention that both heterozygous gain-of-function PRSS1 missense 
variants (Khalid et al., 2006) and heterozygous loss-of-function SPINK1 variants 
have been reported to display variable penetrance (Le Maréchal et al., 2004). 
However, we consider it unlikely that the complete functional loss of 
the SPINK1 gene such as we have described in the current study would manifest 
variable penetrance. 
In summary, we have provided clinical and genetic evidence to define a new pediatric 
disease entity, namely severe infantile isolated EPI. Although the cases we describe were 
both homozygous for null SPINK1 alleles, we might envisage that compound heterozygotes 
comprising two different null SPINK1 alleles should have a same clinical phenotype. Finally, 
we would like to reiterate that the Alu insertion mutation identified here represents the first 
report of an Alu insertion into the 3’-UTR of a human gene causing genetic disease. 
 
FIGURE LEGENDS 
FIGURE 1  Identification of a homozygous deletion of the entire SPINK1 gene in 
case 1. A: The patient’s family pedigree. WT, wild-type. Del, deletion of the 
entire SPINK1 gene. B: Magnetic resonance images of the patient's abdomen at 
five years of age: transverse sections centered on the body and tail of the pancreas 
acquired in T2-weighted image (left subpanel) and with Dixon fat suppression in-
phase (right subpanel), respectively. The pancreas is indicated by an 
arrow. C: Confirmation of the homozygous deletion of the entire four-
exon SPINK1 gene in the patient by QFM-PCR. EPHB6, controlgene. D: The 
patient-specific long-range PCR product (approximately 3.5 kb). HC, healthy 
control. M, DNA marker. E: The sequence spanning the aberrant chromosomal 
junction; an 11 bp insertion was present between the two chromosomal ends. 
This SPINK1 gene deletion was submitted to GenBank 
(https://www.ncbi.nlm.nih.gov/genbank/), its accession number being xxxx. 
FIGURE 2  Identification and functional characterization of a 
homozygous Alu insertion within the 3'-UTR of the SPINK1 gene in case 2. A: The 
patient’s family pedigree. WT, wild-type. Alu, the Alu insertion 
mutation. B: Illustration of the non-amplification of the fourth and last exon of 
the SPINK1 gene in the patient (indicated by an arrow) under standard conditions 
of high-resolution DNA melting analysis. C: Detection of a longer PCR product in 
the patient (homozygous) and her parents (heterozygous) using a longer extension 
time to amplify exon 4 of the SPINK1 gene. HC, healthy control. M, DNA 
marker. D: No detection of specific transcripts from HEK293T cells transfected 
with the Alu mutant construct in a full-length gene assay. The 1000-bp band 
appears to be artefactual because it was also detected in cells transfected with the 
empty pcDNA3.1 vector (EV). The 300-bp band was confirmed by DNA 
sequencing to correspond to the wild-type SPINK1 transcript. NC, negative 
control. E: RT-PCR data from cultured lymphocytes of a healthy control (HC) and 
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